Amgen's UPLIZNA Shows Promise in Treating IgG4-RD

Amgen's UPLIZNA Shows Promise in Treating IgG4-RD

Léa Dubois
2 min read

Amgen's UPLIZNA Shows Promising Results in Treating IgG4-RD

Amgen has unveiled promising outcomes from its Phase III MITIGATE trial, assessing UPLIZNA's efficacy in treating Immunoglobulin G4-related disease (IgG4-RD). The trial, encompassing 135 adults across 80 sites in 22 countries, exhibited an 87% reduction in flare risk compared to placebo, successfully meeting its primary endpoint. Moreover, all crucial secondary endpoints were attained with no new safety concerns, aligning with UPLIZNA's established safety profile. With UPLIZNA's existing approval for neuromyelitis optica spectrum disorder, Amgen is now pursuing regulatory endorsement for its application in treating IgG4-RD in the US and other markets. The company's executive vice-president emphasized the significance of these findings for a disease currently devoid of approved therapies and expressed gratitude to all participants in the study.

Key Takeaways

  • Amgen's Phase III MITIGATE trial demonstrated an 87% reduction in flare risk for IgG4-RD patients using UPLIZNA.
  • The trial encompassed 135 adults across 80 sites in 22 countries, evaluating UPLIZNA against placebo.
  • All critical secondary endpoints, including annualized flare rate and complete remission, were successfully met.
  • No new safety concerns emerged, and the drug's safety profile remained consistent with established norms.
  • Amgen is seeking regulatory approval for UPLIZNA's usage in treating IgG4-RD in the US and other markets.


Amgen's successful Phase III trial for UPLIZNA's application in treating IgG4-RD holds the potential to significantly impact patients and healthcare systems globally. The substantial 87% reduction in flare risk and the achievement of all secondary endpoints without any new safety findings indicate a robust efficacy and safety profile. This development may pave the way for regulatory approval, addressing the gap in approved therapies for IgG4-RD. In the short term, Amgen's stock and market position could strengthen. Over the long term, broader access to UPLIZNA may enhance patient outcomes and decrease healthcare costs linked with IgG4-RD management.

Did You Know?

  • Immunoglobulin G4-related disease (IgG4-RD): A chronic inflammatory condition marked by the infiltration of IgG4-positive plasma cells in various organs, resulting in organ dysfunction and fibrosis. It can impact multiple organs and frequently presents with mass-like effects or diffuse organ enlargement.
  • Phase III Clinical Trial: The phase of clinical research that assesses a drug or treatment's effectiveness in a larger population (typically hundreds to thousands of participants) to confirm its efficacy, monitor side effects, compare it to commonly utilized treatments, and gather information for safe usage.
  • UPLIZNA: A prescription medicine utilized to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive. It is a monoclonal antibody targeting and depleting CD19-positive B cells, implicated in the autoimmune response in NMOSD and potentially in IgG4-RD.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines. The cover photo is computer generated art for illustrative purposes only; not indicative of factual content. If you believe this article infringes upon copyright rights, please do not hesitate to report it by sending an email to us. Your vigilance and cooperation are invaluable in helping us maintain a respectful and legally compliant community.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings